

# Vladimir V Rafalski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3594564/publications.pdf>

Version: 2024-02-01

64  
papers

22,657  
citations

87723

38  
h-index

138251

58  
g-index

70  
all docs

70  
docs citations

70  
times ranked

18135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.	13.9	5,629
2	Angiotensinâ€“Nepriylsin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
3	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
4	Angiotensinâ€“Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
5	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	13.9	1,345
6	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1011-1020.	13.9	1,118
7	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
8	Angiotensin Receptor Nepriylsin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
9	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1215-1226.	13.9	457
10	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2014, 384, 403-413.	6.3	431
11	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
12	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€“converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€“HF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	2.9	358
13	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. <i>New England Journal of Medicine</i> , 2012, 367, 716-724.	13.9	274
14	Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	260
15	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929.	3.6	255
16	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodiumâ€“Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 403-411.	4.3	196
17	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015, 36, 2576-2584.	1.0	187
18	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€“HF</scp>). <i>European Journal of Heart Failure</i> , 2014, 16, 817-825.	2.9	148

#	ARTICLE	IF	CITATIONS
19	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
20	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€“Renal (<sc>CANVASâ€“R</sc>): A randomized, placeboâ€“controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 387-393.	2.2	139
21	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	1.2	118
22	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114
23	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112
24	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016, 68, 241-248.	1.2	101
25	Dementia-related adverse events in <sc>PARADIGMâ€“HF</sc> and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	2.9	95
26	Estimating the Long-Term Treatment Benefits of Sacubitrilâ€“Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92
27	Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 269-277.	2.4	91
28	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
29	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Tj ETQq1 1 0.784314 rgBT /Over Therapy. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	83
30	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
31	1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL. <i>Journal of Hepatology</i> , 2013, 58, S574.	1.8	76
32	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€“mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
33	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	3.6	63
34	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	1.9	63
35	Growth differentiation factorâ€“15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGMâ€“HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
36	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53

#	ARTICLE	IF	CITATIONS
37	Sharing Data from Cardiovascular Clinical Trials – A Proposal. <i>New England Journal of Medicine</i> , 2016, 375, 407-409.	13.9	49
38	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
39	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. <i>European Journal of Heart Failure</i> , 2018, 20, 514-522.	2.9	35
40	Quinolones for uncomplicated acute cystitis in women. <i>The Cochrane Library</i> , 2006, , CD003597.	1.5	34
41	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
42	Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. <i>International Journal of Infectious Diseases</i> , 2016, 51, 47-55.	1.5	28
43	Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 4-9.	1.1	24
44	Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of Ñ€harmacoepidemiological study (FORSIGHT-DM2). <i>Diabetes Mellitus</i> , 2016, 19, 443-456.	0.5	23
45	Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 188-194.	0.9	21
46	Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Ð¢2DM). <i>Diabetes Mellitus</i> , 2017, 20, 403-419.	0.5	18
47	Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment. <i>Laser Physics Letters</i> , 2020, 17, 045601.	0.6	17
48	Prospects for Raman spectroscopy in cardiology. <i>Cardiovascular Therapy and Prevention (Russian)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 0.4 9	0.4	9
49	Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by surface-enhanced Raman spectroscopy. <i>Data in Brief</i> , 2020, 29, 105145.	0.5	7
50	EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION. <i>Urology Herald</i> , 2018, 6, 30-37.	0.1	4
51	Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation. <i>Urology Herald</i> , 2018, 6, 50-56.	0.1	4
52	Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial. <i>Gastroenterology</i> , 2013, 144, S-374.	0.6	3
53	NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring. <i>PLoS ONE</i> , 2021, 16, e0247102.	1.1	3
54	LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2017, 16, 68-75.	0.4	2

#	ARTICLE	IF	CITATIONS
55	The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1470-1476.	0.2	2
56	Spectral homogeneity of human platelets investigated by SERS. <i>PLoS ONE</i> , 2022, 17, e0265247.	1.1	2
57	247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY. <i>Journal of Hepatology</i> , 2010, 52, S104.	1.8	1
58	Single human platelet study using surface-enhanced Raman spectroscopy as a perspective tool for antiplatelet therapy effectiveness prediction. , 2019, , .		1
59	Prospects for Raman spectroscopy in cardiology. <i>Cardiovascular Therapy and Prevention (Russian)</i> Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlook 0.4	0.4	1
60	3-5 DAYS FLUOROQUINOLONES THERAPY IS MORE EFFECTIVE FOR ACUTE UNCOMPLICATED CYSTITIS THEN SINGLE DOSE FOSFOMYCIN: SYSTEMATIC REVIEW AND META-ANALYSIS. <i>European Urology Supplements</i> , 2008, 7, 268.	0.1	0
61	Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice. <i>European Heart Journal</i> , 2013, 34, P2514-P2514.	1.0	0
62	Spectral and time-resolved photoluminescence of human platelets doped with platinum nanoparticles. <i>PLoS ONE</i> , 2021, 16, e0256621.	1.1	0
63	Pharmacokinetic peculiarities of intravenous and oral ciprofloxacin administration in preoperative prophylaxis in patients with benign prostatic hyperplasia. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2014, 12, 64-66.	0.2	0
64	Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. <i>Infektsionnye Bolezni</i> , 2020, 18, 178-189.	0.2	0